Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05069935
Title	FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Recruitment	Terminated
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Fate Therapeutics
Indications	head and neck squamous cell carcinoma triple-receptor negative breast cancer skin squamous cell carcinoma Her2-receptor positive breast cancer esophageal cancer Advanced Solid Tumor endometrial carcinoma renal cell carcinoma lung small cell carcinoma skin melanoma colorectal cancer cervical cancer lung non-small cell carcinoma stomach cancer
Therapies	Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine
Age Groups:	senior \| adult
Covered Countries	USA

Facility	City	State	Zip	Country	Details
Hackensack University Medical Center	Hackensack	New Jersey	07601	United States	Details
Sarah Cannon	Nashville	Tennessee	37203	United States	Details
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	United States	Details
NEXT Oncology	San Antonio	Texas	78229	United States	Details

*Shaded cells indicate that there was no data available from clincialtrials.gov for the field